Ascend Capital’s Cellectis CLLS Stock Holding History

Ascend Capital’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-123,956	Closed	-$3.91M	–	186
2018 Q1	$3.91M	Buy	+123,956	New	+$3.92M	0.16%	132

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Ascend Capital's CLLS Position: Q2 2018 in Review

Ascend Capital sold out of Cellectis (CLLS) in Q2 2018, closing a stake of 123,956 shares — an estimated $3.91M sold.

Ascend Capital first reported a position in CLLS in Q1 2018 and held it in 1 quarter. The position peaked at $3.91M in Q1 2018. 86 funds tracked by Wall St. Rank hold CLLS as of Q2 2018.

Ascend Capital reported no remaining Cellectis position as of Q2 2018 after selling out during the quarter.
Ascend Capital sold 123,956 Cellectis shares in Q2 2018, an estimated $3.91M.
Ascend Capital first reported a position in Cellectis in Q1 2018 and held it in 1 quarter.
Ascend Capital's Cellectis position peaked at $3.91M in Q1 2018.
86 funds tracked by Wall St. Rank held Cellectis as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.